Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Breda Genetics srl | RCV001293770 | SCV001482421 | likely pathogenic | Clark-Baraitser syndrome | 2021-01-22 | criteria provided, single submitter | clinical testing | The variant c.4757+2T>G affects the donor splice site of intron 32 and is therefore highly likely to impact the splicing process by causing the retention of the following intron and the formation of an aberrant mRNA, which is unlikely to be exported and translated into protein. This variant has not been reported in dbSNP, gnomAD, 1000 Genomes Project or ClinVar. Pathogenic splicing mutations in the TRIP12 gene have been previously reported (ClinVar). Almost all pathogenic variants thus far reported are de novo (OMIM # 617752). |